Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05674526 · ClinicalTrials.gov registry record · Phase 1

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

A Phase 1 study of Squamous Cell Carcinoma of Head and Neck and Colorectal Cancer Metastatic, sponsored by Wugen.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT05674526 is a Phase 1 study of Squamous Cell Carcinoma of Head and Neck and Colorectal Cancer Metastatic that is active but no longer recruiting, run by Wugen. The registered enrollment target is 30 participants, below the 170-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05674526, a Phase 1 study of Squamous Cell Carcinoma of Head and Neck and Colorectal Cancer Metastatic, is active but no longer recruiting, sponsored by Wugen.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort 1), and in patients with advanced and/or metastatic SCCHN (Cohort 2). The overall study will be comprised of two phases, a Dose Escalation Phase, and a Cohort Expansion Phase.

Conditions Studied

Squamous Cell Carcinoma of Head and Neck Colorectal Cancer Metastatic

Interventions

  • BIOLOGICAL WU-NK-101 - Dose Escalation
  • DRUG Cetuximab - Dose Escalation
  • BIOLOGICAL WU-NK-101 - Cohort Expansion
  • BIOLOGICAL Cetuximab - Cohort Expansion

Study Locations (2)

California

  • UCSF - San Francisco

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-05-21
Est. Completion 2026-06-01
Phase Phase 1

Sponsor

Wugen

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05674526

The ClinicalTrials.gov registry entry for NCT05674526 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (82% lower). The listed sponsor is Wugen, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 4 interventions - of which WU-NK-101 - Dose Escalation is the first listed.

NCT05674526 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.

Frequently Asked Questions

What is clinical trial NCT05674526 about?

NCT05674526 is a clinical study titled "A Phase 1b Study of WU-NK-101 in Combination With Cetuximab". This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort 1), and in patients with advanced and/or metastatic SCCHN (Cohort 2). Th...

What is the current status of trial NCT05674526?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-05-21. Estimated completion is 2026-06-01.

What conditions does trial NCT05674526 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer Metastatic.

What interventions are being tested in trial NCT05674526?

The interventions under investigation include: WU-NK-101 - Dose Escalation (BIOLOGICAL), Cetuximab - Dose Escalation (DRUG), WU-NK-101 - Cohort Expansion (BIOLOGICAL), Cetuximab - Cohort Expansion (BIOLOGICAL).

Who is sponsoring clinical trial NCT05674526?

This trial is sponsored by Wugen, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05674526 being conducted?

This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Cell Carcinoma of Head and Neck

All registered trials for this condition

Colorectal Cancer Metastatic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.